Search Results

Your search for Kevin Knopf, MD, MPH, and Charles Bennett, MD, PhD, MPP,Kevin Knopf, MD, MPH, and Charles Bennett, MD, PhD, MPP matches 2 pages

Showing 1 - 2

By Kevin B. Knopf, MD, MPH, and Charles L. Bennett, MD, PhD, MPP / January 25, 2024

Generic Drug Shortages and Essential Cancer Medicines

Decisions regarding the rationing of chemotherapy are commonplace in many countries around the world—including those where patients must pay for chemotherapy out of pocket—and increasingly so in cancer settings that treat both well-off and socioeconomically disadvantaged patients. However, these...

cost of care

By Kevin Knopf, MD, MPH, and Charles Bennett, MD, PhD, MPP / July 10, 2017

The Emperor’s New Clothes: Biosimilars and Cost in Oncology

Biosimilars are biologic products similar to the parent (branded) molecule in structure and function—such as erythropoietin and filgrastim (Neupogen).1 To truly bend the cost curve, we want to see a dramatic economic savings achieved as oncology biosimilars for rituximab (Rituxan), trastuzumab...

Nov

Today In Oncology

Search Results

Your search for Kevin Knopf, MD, MPH, and Charles Bennett, MD, PhD, MPP,Kevin Knopf, MD, MPH, and Charles Bennett, MD, PhD, MPP matches 2 pages

Generic Drug Shortages and Essential Cancer Medicines

The Emperor’s New Clothes: Biosimilars and Cost in Oncology

What Is the Impact of a Colon or Colorectal Cancer Diagnosis on Younger Adults?

International Cancer Organizations Present Collaborative Work During Oncology Event in China

Is There a Role for Neoadjuvant Chemotherapy in HR-Positive, HER2-Negative Early Breast Cancer?

Suicide-Related Mortality in Male AYA Cancer Survivors

Four-Year Asian Subpopulation Data From the CheckMate 816 Trial of Neoadjuvant Nivolumab Plus Chemotherapy in Resectable NSCLC